CCCC — C4 Therapeutics Share News
0.000.00%
Last trade - 00:00- $391.22m
- $137.56m
- $35.95m
Brief: C4 Therapeutics Q3 EPS USD -0.44
C4 Therapeutics rallies after premium-priced $125 mln equity offering
U.S. STOCKS ON THE MOVE-Nike, Occidental Petroleum, Veeco Instruments
C4 Therapeutics climbs after partnership with Pfizer for cancer therapy trial
Brief: C4 Therapeutics, Pfizer Partner on Trial Combining Cemsidomide and Elranatamab for Relapsed/Refractory Multiple Myeloma
Brief: C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-In-Class Profile At The International Myeloma Society Annual Meeting
C4 Therapeutics Inc expected to post a loss of 38 cents a share - Earnings Preview
C4 Therapeutics Inc expected to post a loss of 38 cents a share - Earnings Preview
C4 Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: C4 Therapeutics Q1 EPS USD -0.37
C4 Therapeutics Inc expected to post a loss of 45 cents a share - Earnings Preview
C4 Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
C4 Therapeutics Inc expected to post a loss of 48 cents a share - Earnings Preview
C4 Therapeutics Inc expected to post a loss of 48 cents a share - Earnings Preview
Brief: C4 Therapeutics Data In Melanoma & Colorectal Cancer Expected In Second Half Of 2025
Brief: C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter To Board Of Directors
U.S. RESEARCH ROUNDUP- Equifax, Microstrategy, Netflix
Brief: C4 Therapeutics Inc Files For Stock Shelf Offering Of Up To $200 Million - SEC Filing
C4 Therapeutics Inc reports results for the quarter ended in September 30 - Earnings Summary